NIKKEI 225
38,229.11 -44.99 (-0.12%) HANG SENG
18,963.68 +487.78 (+2.64%) CRUDE OIL
78.06 -0.20 (-0.26%) GOLD FUTURES
2,366.70 -8.30 (-0.35%) DOW
39,512.84 +837.14 (+2.16%) Bitcoin GBP
49,106.78 +555.31 (+1.14%)
Novartis AG (NOVNZ.XC)
| Previous close | 90.51 |
| Open | 91.41 |
| Bid | 0.00 x 0 |
| Ask | 92.22 x 0 |
| Day's range | 91.12 - 92.38 |
| 52-week range | 79.19 - 94.52 |
| Volume | |
| Avg. volume | 543,378 |
| Market cap | 188.167B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 23.17 |
| EPS (TTM) | 3.98 |
| Earnings date | 18 Jul 2024 |
| Forward dividend & yield | 3.30 (3.58%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
GlobeNewswireArvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
The TelegraphQuestor: this medical stock is expensive – but worth paying for
It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.
ZacksAlnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
